A study published Wednesday in the journal Neurology suggests that a longer reproductive span—the years between a woman’s first period and menopause—correlates with healthier brain aging in later life. Researchers found that women with more years of natural estrogen exposure showed less damage to the brain’s small blood vessels and better-preserved white matter at age 70.
The study, which examined 352 cognitively healthy women, also identified a potential, more provocative link: participants who used both oral contraceptives and hormone therapy exhibited the healthiest brain profiles of the group. Anna Marseglia, the study’s senior author and an assistant professor of aging epidemiology and brain health at the Karolinska Institute in Stockholm, said, "I was personally very excited," The Washington Post reported.
The Role of Estrogen Exposure
For decades, the medical community has debated the risks and benefits of hormone therapy. Following a landmark 2002 Women’s Health Initiative study that linked the treatment to increased risks of breast cancer, heart disease, and stroke, prescriptions in the United States dropped by nearly 40 percent in a single year.
However, recent scientific reassessments suggest that timing is critical. Researchers now posit a "critical window hypothesis," where the brain may respond differently to estrogen depending on when therapy is introduced. Evidence accumulated over the last two decades suggests that starting hormone therapy near the onset of menopause may yield different outcomes than initiating treatment years after the body has ceased natural estrogen production.
Shifting Medical Guidelines
Major health organizations have recently updated their stances on hormone therapy to reflect this evolving data. Late last year, the Food and Drug Administration moved to lift a black-box warning that had been associated with the 2002 study. The American College of Obstetricians and Gynecologists (ACOG) recommends hormone therapy as a first-line treatment for menopausal symptoms like hot flashes and night sweats. The American College of Physicians issued similar recommendations on Oct. 5.
While these groups support hormone therapy for symptom management, they do not currently recommend it as a preventive measure for dementia or Alzheimer’s disease. Caroline Just, a neurologist at the Cleveland Clinic, noted that while the research is promising, the clinical evidence for neurological protection remains incomplete. "The reasons to get hormone therapy are all non-neurological," Just stated. "At this stage, we lack the data to support its use for those looking to lower their dementia risk."
Factors Influencing Brain Health
Scientists are increasingly investigating how vascular health, diet, and underlying conditions like Type 2 diabetes interact with hormone therapy. Jill Daniel, a professor of brain science at Tulane University, observed that in animal models, the benefits of estrogen on memory can reverse in the presence of high blood pressure or high-fat diets.
Future studies aim to determine if a "tipping point" exists where the brain’s capacity to respond to estrogen diminishes. "We cannot really deny that we see an association, a possible beneficial impact," Marseglia said. "Our goal is to confirm whether this applies to every woman, and to pinpoint the specific circumstances and timing that matter most."
Hormone Therapy Remains Restricted to Menopausal Symptoms Rather than Dementia Prevention
Is hormone therapy now recommended to prevent Alzheimer’s disease?
No. While recent studies show an association between hormone therapy and better brain health markers, both the American College of Obstetricians and Gynecologists and the American College of Physicians currently only recommend the treatment for managing menopausal symptoms like night sweats and hot flashes.
Why did previous studies link hormone therapy to higher risks of dementia?
A major 2003 study found that women taking estrogen plus progestin had roughly twice the risk of probable dementia compared to those on a placebo. However, researchers now point out that the participants in that study were 65 or older, suggesting that the timing of when a woman begins treatment is a decisive factor in the risk-benefit profile.
What is the "critical window" for hormone therapy?
The critical window refers to the period around the onset of menopause. Scientists suspect that the brain’s receptors respond more favorably to estrogen when it is introduced before the body has gone many years without the hormone. Current ACOG guidelines generally suggest that treatment should begin before age 60 or within 10 years of the onset of menopause.
Keep reading